BioNTech stock price increased greatly over the year

The Coronavirus Covid-19 Pandemic needs treatments and vaccines. Investors are interested in the biotech sector for stocks that perform well. Now seems like a good time to invest in biotech stocks. Shares of BioNTech have increased more than 300% since the company's IPO last October. BioNTech stock price is impressive.

BioNTech SE (NASDAQ:BNTX) is an exciting German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. It researches drugs based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. The company developed an mRNA-based human therapeutic for intravenous administration, to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.

BioNTech's (NASDAQ:BNTX) partnership with Pfizer (NYSE:PFE) is interesting. The 2 companies are currently leading the race for a COVID-19 vaccine with their messenger RNA candidate BNT162b2. The candidate is now in phase 3 clinical testing after delivering a robust immune response against SARS-CoV-2 to almost all participants in phase 1.

Governments of various countries are interested in these studies. If the vaccine is successful in these studies, countries (such as USA and the E.U.) could order millions of doses. BioNTech stock price could go up greatly, if successful.

Next year, BioNTech expects to have the capacity to produce 250 million doses of BNT162b2 every six months (enough for 125 million people). At a certain price of $19.50 per dose - that could be $9.75 billion in annual revenue. The company has a market cap of $15 billion. BioNTech stock price has much room for increasing. BioNTech market share could increase.

On Sept. 15, the company achieved receiving a 375-million-euro grant from the German Federal Ministry of Education and Research for its COVID-19 vaccine program. Look forward to more interesting Data from Pfizer and BioNTech's experimental vaccine (data coming next month).

BioNTech is also working with Fosun Pharma. BioNTech and Fosun Pharma announced (on Aug. 05, 2020) the start of clinical trial of mRNA-based COVID-19 vaccine candidate in China. Read more about it here: https://www.globenewswire.com/news-release/2020/08/05/2073035/0/en/BioNTech-and-Fosun-Pharma-Announce-Start-of-Clinical-Trial-of-mRNA-based-COVID-19-Vaccine-Candidate-in-China.html

Here are the BioNTech SE - Subsidiaries:

BioNTech Innovative Manufacturing Services GmbH

BioNTech Delivery Technologies GmbH

BioNTech Small Molecules GmbH

BioNTech US Inc.

BioNTech Diagnostics GmbH

Biontech Rna Pharmaceuticals Gmbh

BioNTech Cell & Gene Therapies GmbH

BioNTech Research and Development, Inc.